Certara (CERT) Scheduled to Post Quarterly Earnings on Wednesday

Certara (NASDAQ:CERT - Get Free Report) will release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Certara to post earnings of $0.11 per share for the quarter. Certara has set its FY24 guidance at $0.41 to $0.46 EPS.Parties that are interested in registering for the company's conference call can do so using this link.

Certara (NASDAQ:CERT - Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The firm had revenue of $93.31 million during the quarter, compared to analysts' expectations of $96.01 million. During the same period last year, the firm posted $0.10 earnings per share. The firm's quarterly revenue was up 3.2% on a year-over-year basis. On average, analysts expect Certara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Certara Stock Down 0.4 %

Shares of CERT traded down $0.04 on Wednesday, hitting $10.31. 1,121,306 shares of the stock traded hands, compared to its average volume of 774,307. Certara has a one year low of $9.99 and a one year high of $19.87. The company has a market capitalization of $1.66 billion, a PE ratio of -20.62, a P/E/G ratio of 5.40 and a beta of 1.49. The business has a 50 day simple moving average of $11.33 and a 200 day simple moving average of $13.97. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Robert W. Baird dropped their price objective on Certara from $19.00 to $18.00 and set a "neutral" rating on the stock in a research report on Wednesday, August 7th. JMP Securities reiterated a "market perform" rating on shares of Certara in a research note on Wednesday, July 10th. KeyCorp dropped their target price on shares of Certara from $23.00 to $20.00 and set an "overweight" rating on the stock in a report on Thursday, July 11th. Barclays lowered their price target on Certara from $16.00 to $14.00 and set an "equal weight" rating on the stock in a report on Tuesday, October 15th. Finally, UBS Group upgraded Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target for the company in a research note on Friday, September 27th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $17.08.

Insider Buying and Selling

In related news, insider Patrick F. Smith sold 5,409 shares of the business's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares of the company's stock, valued at approximately $552,503.73. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now owns 50,091 shares in the company, valued at $552,503.73. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Leif E. Pedersen sold 51,224 shares of the firm's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares of the company's stock, valued at $1,125,658.16. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by insiders.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.